UroGen Pharma Ltd [URGN] stock prices are up 3391041% to $2690000.0 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The URGN shares have gain 32.22% over the last week, with a monthly amount glided 94.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on June 16, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $50 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on May 22, 2025. On April 16, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $23 on the stock. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on August 22, 2024. Jefferies downgraded its rating to Hold for this stock on February 08, 2023, and downed its price target to $10. In a note dated April 27, 2022, Berenberg initiated an Buy rating and provided a target price of $20 on this stock.
The stock price of UroGen Pharma Ltd [URGN] has been fluctuating between $3.42 and $18.15 over the past year. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $2690000.0 at the most recent close of the market. An investor can expect a potential drop of -100.0% based on the average URGN price forecast.
Analyzing the URGN fundamentals
The UroGen Pharma Ltd [NASDAQ:URGN] reported sales of 91.87M for trailing twelve months, representing a surge of 7.84%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -1.47%, and Net Profit Margin reading is -1.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -974.87 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that UroGen Pharma Ltd [NASDAQ:URGN]’s Current Ratio is 5.65. In addition, the Quick Ratio stands at 5.47 and the Cash Ratio stands at 2.48. Considering the valuation of this stock, the price to sales ratio is 7.35.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Jun 09 ’25 when 5162.0 shares were sold. Officer, Schoenberg Mark completed a deal on Jun 09 ’25 to buy 5162.0 shares. Meanwhile, Chief Medical Officer Schoenberg Mark sold 4551.0 shares on Jan 31 ’25.
